Myeloproliferative Neoplasm Quality of Life

~ International Study Group ~

For MPN-QOL Investigators

For MPN Healthcare Providers

Decrease Font Size
Increase Font Size

MPN-QOL Papers

Many patients and their providers find it useful to stay informed on the latest data regarding MPN research. Listed below are key research articles that have helped to shape our understanding MPN symptoms and quality of life (QOL). Click on the links below to find abstracts for these documents.

 

Articles:
Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68-76.
Click Here to Read

Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA.  Common troublesome symptoms and their impact on quality of life in patients with myelodysplastic syndromes (MDS): results of a large internet-based survey.  Leuk Res 2008 May; 32(5):691-8.
Click Here to Read


Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis.  Leuk Res. 2009 Sep;33(9):1199-203.
Click Here to Read

Mesa RA. Assessing new therapies and their overall impact in myelofibrosis. Hematology Am Soc Hematol Educ Program. 2010: 115-21.
Click Here to Read


Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011 Jul 14;118(2):401-8.
Click Here to Read

Mesa RA, Kantarjian H, Tefferi A, Dueck A, Levy R, Vaddi K, Erickson-Viitanen S, Thomas DA, Cortes J, Borthakur G, Pardanani AD, Estrov Z, Verstovsek S. Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.  Cancer. 2011 Nov 1;117(21):4869-77.
Click Here to Read


Johansson P, Mesa R, Scherber R, Abelsson J, Samuelsson J, Birgegård G, Andréasson B. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms.  Leuk Lymphoma. 2012 Mar;53(3):441-4.
Click Here to Read

Abstracts:

Mesa RA, Wadleigh M, Niblack J, Gilliland DG, Verstovsek S, Camoriano J, Solberg L, Barnes S, Sloan J, Atherton P, Tan A, Tefferi A.  Fatigue, the un-addressed curse of myeloproliferative diseases (MPD): results of an international inernet based QOL survey of 830 MPD patients (Abstract 2577).  Blood 2005 Nov; 106(11):724a-725a.  (Abstract)

Mesa RA, Niblack J, Tan AD, Atherton PJ, Sloan JA, Tefferi A.  Phlebotomy vs. myelosuppressive medications in controlling erythrocytosis in polycythemia vera (PV) patients: impact upon fatigue in a survey of 405 PV patients (Abstract 4883).  Blood 2006 Nov; 108(11 part 2):307b.  (Abstract)

 Mesa RA, Niblack J, Wadleigh M, Gilliland DG, Verstovsek S, Kantarjian H, Camoriano J, Solberg L, Varnes S, Tan A, Atherton P, Sloan J, Tefferi A.  The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet based survey of 1179 MPD patients (Abstract 4872).  Blood 2006 Nov; 108(11 part 2):304b.  (Abstract)

Steensma DP, Heptinstall KV, Johnson VM, Novotny PJ, Sloan JA, Camoriano JK, Niblack J, Bennett JM, Mesa RA.  Common troublesome symptoms and their impact on health-related quality of life (QoL) in 359 patients with myelodysplastic syndromes (MDS): results of an internet-based survey.  Leuk Res 2007 May; 31(Suppl 1):S106.  (Abstract)

Mesa RA, Schwager S, Huang J, Hussein K, Pardanani AD, Tefferi A.  Dynamics, and Prognostic Impact, of Weight Loss in Primary Myelofibrosis.  Blood 2008; 112(11):a5224.  (Abstract)

Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Tefferi A.  Assessment and monitoring of constitutional symptoms in patients with myelofibrosis: a proposed new instrument the myelofibrosis symptom assessment form (MFSAF).  Blood 2008 Nov; 112(11):619.  (Abstract)

Mesa RA, Schwager S, Huang J, Pardanani AD, Hussein K, Camoriano J, Tefferi A.  Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 inhibitor era.  Blood 2009 Nov 20; 114(22):1507.  (Abstract)

Scherber, R.M., Dueck, A.C., Johansson, P.L., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Harrison, C., Radia, D. and Mesa, R.A. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): An International Prospective Validation Trial In 402 Patients. An abstract presented at the American Society of Hematology, December 2010, Orlando, FL, U.S.A.

Scherber, R.M., Barbui, T., Vannucchi, A.M., Passamonti, F., Barosi, G., Rambaldi, A., Ferarri, M.L., Dueck, A.C., Tefferi, A., and Mesa, R.A. Prospective Validation of the Italian Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Italian) In 186 MPN Patients. An abstract submitted to the American Society of Hematology, December 2010, Orlando, FL, U.S.A.

Johansson, P.L., Andreasson, B., Scherber, R.M.,  Dueck, A.C.,  Samuelsson, J.,  Birgegard, G., Tefferi, A.,  and Mesa, R.A. Prospective Validation of the Swedish Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF: Swedish) In 114 MPN Patients. An abstract submitted to the American Society of Hematology, December 2010, Orlando, FL, U.S.A.

Mesa, R.A., Scherber, R.S., Dueck, A., Camoriano, J., Gentry, A., Reeder, C., Baumgartner, K., Radia, D., Tefferi, A., Harrison, C. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): Prospective Validation of an Evidence Based MPN Specific Instrument. An abstract presented at the European Hematology Association, June, 2010, Barcelona, Spain.

Scherber, R.M., Dueck, A.C., Kiladjian, J.J., Slot, S., Zweegman, S., te Boekhorst, P.W., Commandeur, S., Schouten, H., Sackmann, F., Fuentes, A.K., Hernández-Maraver, D.,  Pahl, H.L, Griesshammer, M., Stegelmann, F., Doehner, K., Lehmann, T., Bonatz, K., Reiter, A., Boyer, F.,  Etienne, G.,  Ianotto, J.C. , Ranta, D., Roy, R.,  Cahn, J.Y., Harrison, C.N.,  Radia, D., Muxi, P., Monaldo, N., Besses, C., Cervantes, F., Johansson, P.L., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A. and Mesa, R.A. The Myleloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs). An abstract presented at to the American Society of Hematology, December 2011, San Diego, CA, U.S.A. Blood 2011 118(21): a3839.

Scherber RM, Dueck AC, Jean-Jacques K, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY,  Harrison CN,  Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. The Burden of Myelofibrosis: Prospective Symptomatic International Assessment in 293 Patients. Poster presented at the 6th  International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes; 2011 Nov 3-4; New York, NY. P04.

Roda P, Scherber RM, Dueck A, Miles E, Mesa RA. Symptomatic burden in a cohort of JAK2V617F positive, low allele burden residents without clinical disease detected in a screening study of the NEPA PV Cluster. An abstract submitted to the 6th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, Nov 3-4 2011, New York, N.Y. P14.

Scherber, R.M., Kiladjian, J.J., Dueck, A., Slot, S., Zweegman, S., te Boekhorst, P.W., Commandeur, S., Schouten, H., Sackmann, F., Fuentes, A.K., Hernández-Maraver, D.,  Pahl, H.L, Harrison, C.N.,  Radia, D., Muxi, P., Monaldo, N., Besses, C., Cervantes, F., Tefferi, A. and Mesa, R.A. Validation of the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) in French, Spanish, German, and English (UK). An abstract presented at the European Hematological Association, June 2011, London, U.K.

Kiladjian, J.J., Scherber, R.M.,  Dueck, A., Tefferi, A., and Mesa, R.A. Symptomatic Burden of Myeloproliferative Neoplasms (MPN) in France: A Prospective Trial of 482 Patients. An abstract presented at the European Hematological Association, June 2011, London, U.K.

Scherber, R.M., Dueck, A.C., Johansson, P.L., Barbui, T., Barosi, G., Vannucchi, A.M., Passamonti, F., Andreasson, B., Ferarri, M.L., Rambaldi, A., Samuelsson, J., Birgegard, G., Tefferi, A., Monaldo, N., Sackmann, F., Muxi, P., Hernández-Maraver, D., Kiladjian, J.J. and Mesa, R.A.. Symptomatic Burden in Myelofibrosis: Prospective International Assessment in 128 MF Patients [abstract]. Proceedings of the 2011 ASCO Annual Meeting; 2011 Jun 4-8; Chicago, IL. Washington, DC: Journal of Clinical Oncology; 2011. 29(15):6610.

Last Updated Tuesday, July 25, 2017 - 08:49 PM.